Clinical Trials
17 trialsNCT07598955 2026-05-20
SELECT-NK-THYM
Beijing Biotech
Phase 1/2 Recruiting
NCT07324629 2026-05-07
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2 Not yet recruiting
NCT05544929 2026-01-06
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Phase 1 Active not recruiting
NCT05150210 2025-12-23
SP Thoracic IDE Study
Intuitive Surgical
Phase NA Active not recruiting
NCT07181720 2025-10-02
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
Phase 1 Recruiting
NCT04321330 2024-06-11
A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma
Hoffmann-La Roche
Phase 2 Completed
NCT05682742 2024-06-03
Clinical Investigation of the da Vinci Surgical System
Intuitive Surgical
Phase NA Active not recruiting
NCT04469725 2024-03-12
KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2 Terminated
NCT04430842 2023-01-18
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
Phase 1 Completed
NCT03517488 2022-12-01
DUET-2
Xencor, Inc.
Phase 1 Completed
NCT03102320 2022-06-30
ARCS-Multi
Bayer
Phase 1 Completed
NCT01011439 2019-02-06
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
Tiziana Life Sciences LTD
Phase 2 Terminated
NCT01301391 2019-02-06
Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy
Tiziana Life Sciences LTD
Phase 2 Terminated
NCT00332969 2017-03-31
Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma
Novartis
Phase 2 Completed
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT01242072 2012-07-18
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
Alaunos Therapeutics
Phase 1 Unknown